

Prodotti scientifici (2023-2024):

1. [Role of Lipoprotein\(a\) in Cardiovascular diseases and premature acute coronary syndromes \(RELACS study\): Impact of Lipoprotein\(a\) levels on the premature coronary event and the severity of coronary artery disease.](#)
Cesaro A, Acerbo V, Scialla F, Scherillo G, De Michele G, Panico D, Porcelli G, de Sio V, Capolongo A, Sperlongano S, Ruggiero A, Gragnano F, Moscarella E, Averna M, Calabrò P.
Nutr Metab Cardiovasc Dis. 2024 Dec 24;103843. doi: 10.1016/j.numecd.2024.103843.
PMID: 39934048
2. [Antithrombotic therapy in patients with atrial high-rate episodes \(AHREs\): Current evidence and open questions.](#)
De Sio V, Gragnano F, Capolongo A, Terracciano F, Maddaluna P, Guarnaccia N, Verde G, Cesaro A, Moscarella E, Costa F, Galli M, Sabouret P, Pelliccia F, Grove EL, Calabrò P.
Int J Cardiol. 2025 Mar 1;422:132921. doi: 10.1016/j.ijcard.2024.132921. Epub 2024 Dec 19.
PMID: 39708905 Review.
3. [Navigating the complexity of bleeding and hypercoagulable disorders in patients with acute myocardial infarction.](#)
Gragnano F, Angiolillo DJ.
Cardiovasc Revasc Med. 2024 Dec 5:S1553-8389(24)00745-0. doi: 10.1016/j.carrev.2024.11.015. Online ahead of print.
PMID: 39665950 No abstract available.
4. [SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation \(TAVI\).](#)
Paolisso P, Belmonte M, Gallinoro E, Scarsini R, Bergamaschi L, Portolan L, Armillotta M, Esposito G, Moscarella E, Benfari G, Montalto C, Shumkova M, de Oliveira EK, Angeli F, Orzalkiewicz M, Fabroni M, Baydaroglu N, Munafò AR, D'Atri DO, Casenghi M, Scisciola L, Barbieri M, Marfella R, Gragnano F, Conte E, Pellegrini D, Ielasi A, Andreini D, Penicka M, Oreglia JA, Calabrò P, Bartorelli A, Pizzi C, Palmerini T, Vanderheyden M, Saia F, Ribichini F, Barbato E.
Cardiovasc Diabetol. 2024 Nov 21;23(1):420. doi: 10.1186/s12933-024-02504-8.
PMID: 39574095 Free PMC article.
5. [Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions.](#)
Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R, Capodanno D, Valgimigli M, Mehran R, Perrone Filardi P, Cirillo P, Angiolillo DJ; Working Group of Thrombosis of the Italian Society of Cardiology.
JACC Cardiovasc Interv. 2024 Oct 28;17(20):2325-2336. doi: 10.1016/j.jcin.2024.09.011.
PMID: 39477636 Review.
6. [Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention.](#)

Gragnano F, van Klaveren D, Heg D, Räber L, Krucoff MW, Raposeiras-Roubín S, Ten Berg JM, Leonardi S, Kimura T, Corpataux N, Spirito A, Hermiller JB, Abu-Assi E, Chan Pin Yin D, Azzahhafi J, Montalto C, Galazzi M, Bär S, Kavaliauskaite R, D'Ascenzo F, De Ferrari GM, Watanabe H, Steg PG, Bhatt DL, Calabrò P, Mehran R, Urban P, Pocock S, Windecker S, Valgimigli M.

Circulation. 2025 Feb 11;151(6):343-355. doi: 10.1161/CIRCULATIONAHA.124.072009. Epub 2024 Oct 27.

PMID: 39462482

7. [Ticagrelor Therapy Modifications after Acute Coronary Syndrome: An Ever-Evolving Issue.](#)

Gragnano F, Angiolillo DJ.

Thromb Haemost. 2024 Nov 18. doi: 10.1055/a-2448-7029. Online ahead of print.

PMID: 39447613 No abstract available.

8. [Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions.](#)

Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R, Capodanno D, Valgimigli M, Mehran R, Perrone Filardi P, Cirillo P, Angiolillo DJ; Working Group of Thrombosis of the Italian Society of Cardiology.

JACC Cardiovasc Interv. 2024 Oct 14;17(19):2197-2215. doi: 10.1016/j.jcin.2024.08.022.

PMID: 39415380 Review.

9. [2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?](#)

Galli M, Gragnano F, Vrints C, Andreotti F.

Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):572-574. doi: 10.1093/ehjcvp/pvae069.

PMID: 39289001 No abstract available.

10. [ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor.](#)

Benenati S, Gragnano F, Scalamera R, De Sio V, Capolongo A, Cesaro A, Annibali G, Campagnuolo S, Silverio A, Bellino M, Centore M, Schettino M, Bertero E, Caretta G, Rezzaghi M, Veneziano F, De Nardo D, De Rosa G, De Luca L, Galasso G, Menozzi A, Musumeci G, Cirillo P, Calabrò P, Porto I.

Int J Cardiol. 2024 Dec 15;417:132568. doi: 10.1016/j.ijcard.2024.132568. Epub 2024 Sep 14.

PMID: 39284439

11. [OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold.](#)

Gragnano F, Capolongo A, Galli M, Calabrò P.

Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):575-577. doi: 10.1093/ehjcvp/pvae065.

PMID: 39257276

12. [De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.](#)

Valgimigli M, Hong SJ, Gragnano F, Chalkou K, Franzone A, da Costa BR, Baber U, Kim BK, Jang Y, Chen SL, Stone GW, Hahn JY, Windecker S, Gibson MC, Song YB, Ge Z, Vranckx P, Mehta S, Gwon HC, Lopes RD, Dangas GD, McFadden EP, Angiolillo DJ, Leonardi S, Heg D, Calabrò P, Jüni P, Mehran R, Hong MK; Single Versus Dual Antiplatelet Therapy (Sidney-4) collaborator group.

Lancet. 2024 Sep 7;404(10456):937-948. doi: 10.1016/S0140-6736(24)01616-7. Epub 2024 Aug 31.

PMID: 39226909

13. [Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions.](#)

Montone RA, Rinaldi R, Niccoli G, Andò G, Gragnano F, Piccolo R, Pelliccia F, Moscarella E, Zimarino M, Fabris E, de Rosa S, Calabrò P, Porto I, Burzotta F, Grigioni F, Barbato E, Chieffo A, Capodanno D, Al-Lamee R, Ford TJ, Brugaletta S, Indolfi C, Sinagra G, Perrone Filardi P, Crea F; Interventional Cardiology Working Group of the Italian Society of Cardiology.

J Am Coll Cardiol. 2024 Aug 20;84(8):744-760. doi: 10.1016/j.jacc.2024.06.015.

PMID: 39142729 Review.

14. [Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial.](#)

Gragnano F, De Sio V, Cesaro A, Calabrò P.

Future Cardiol. 2024;20(11-12):591-593. doi: 10.1080/14796678.2024.2388472. Epub 2024 Aug 12.

PMID: 39129704

15. [Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention.](#)

Pelliccia F, Niccoli G, Zimarino M, Andò G, Porto I, Calabrò P, De Rosa S, Gragnano F, Piccolo R, Moscarella E, Fabris E, Montone RA, Spaccarotella C, Indolfi C, Sinagra G, Filardi PP; Working Group of Interventional Cardiology of the Italian Society of Cardiology.

Rev Cardiovasc Med. 2023 Dec 25;24(12):365. doi: 10.31083/j.rcm2412365. eCollection 2023 Dec.

PMID: 39077094

16. [P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis.](#)

Galli M, Laudani C, Occhipinti G, Spagnolo M, Gragnano F, D'Amario D, Navarese EP, Mehran R, Valgimigli M, Capodanno D, Angiolillo DJ.

Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):588-598. doi:

10.1093/ehjcvp/pvae057.

PMID: 39054275

17. [Low platelet count at admission has an adverse impact on outcome in patients with acute coronary syndromes: from the START Antiplatelet registry.](#)

Gresele P, Guglielmini G, Del Pinto M, Calabrò P, Pignatelli P, Patti G, Pengo V, Antonucci E, Cirillo P, Fierro T, Palareti G, Marcucci R; START Antiplatelet Registry Group.

Sci Rep. 2024 Jun 24;14(1):14516. doi: 10.1038/s41598-024-64113-5.

PMID: 38914608 Free PMC article.

18. [Aspirin-Free Strategies After Complex PCI: Type of P2Y₁₂ Inhibitor Matters.](#)

Gragnano F, Calabrò P.

JACC Cardiovasc Interv. 2024 May 13;17(9):1131-1133. doi: 10.1016/j.jcin.2024.03.026.

PMID: 38749593 No abstract available.

19. [The hidden bridging of left anterior descending artery.](#)

Ronza FM, Di Gennaro TL, Gragnano F, Golia E, Iodice M, Posillico G, Rucco MA, Pariggiano I, Sullo P, Calabrò P.

J Cardiovasc Med (Hagerstown). 2024 Sep 1;25(9):713-714. doi: 10.2459/JCM.0000000000001620. Epub 2024 Apr 2.

PMID: 38625828 No abstract available.

20. [Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry.](#)

Caforio ALP, Kaski JP, Gimeno JR, Elliott PM, Laroche C, Tavazzi L, Tendera M, Fu M, Sala S, Seferovic PM, Heliö T, Calò L, Blagova O, Amin A, Kindermann I, Sinagra G, Frustaci A, Bonnet D, Charron P, Maggioni AP; CMY Registry Investigators.

Eur Heart J. 2024 Jul 21;45(28):2548-2569. doi: 10.1093/eurheartj/ehae169.

PMID: 38594778

21. [Long-term antithrombotic therapy in patients with atrial fibrillation and PCI: antiplatelets are fired.](#)

Gragnano F, Calabrò P.

EuroIntervention. 2024 Apr 1;20(7):e400-e401. doi: 10.4244/EIJ-E-23-00067.

PMID: 38562066 No abstract available.

22. [A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience.](#)

Procopio A, Radico F, Gragnano F, Ghiglieno C, Fassini G, Filtz A, Barbarossa A, Sacchetta D, Faustino M, Ricci F, Russo AD, Calabrò P, Patti G, Gallina S, Renda G.

Int J Cardiol Heart Vasc. 2024 Mar 22;51:101391. doi: 10.1016/j.ijcha.2024.101391.

eCollection 2024 Apr.

PMID: 38560514 Free PMC article.

23. [Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.](#)

Valgimigli M, Gragnano F, Branca M, Franzone A, da Costa BR, Baber U, Kimura T, Jang Y, Hahn JY, Zhao Q, Windecker S, Gibson CM, Watanabe H, Kim BK, Song YB, Zhu Y, Vranckx P, Mehta S, Ando K, Hong SJ, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Calabrò P, Jüni P, Mehran R; Single Versus Dual Antiplatelet Therapy (Sidney-3) Collaboration.

JAMA Cardiol. 2024 May 1;9(5):437-448. doi: 10.1001/jamacardio.2024.0133.

PMID: 38506796

24. [Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and Potential Therapeutic Strategies-A Review.](#)

Bruoha S, Galli M, Sabouret P, Yosefy C, Taha L, Gragnano F, Savage MP, Shuvy M, Biondi-Zoccai G, Glikson M, Asher E.

J Cardiovasc Pharmacol. 2024 Jun 1;83(6):547-556. doi: 10.1097/FJC.0000000000001554.

PMID: 38421206 Review.

25. [Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives.](#)

Kulasingam A, Pareek M, Gragnano F, Würtz M, Pryds K, Calabrò P, Grove EL.

Cardiology. 2024;149(5):502-512. doi: 10.1159/000537706. Epub 2024 Feb 14.

PMID: 38354713 Review.

26. [Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.](#)

Gragnano F, Capolongo A, Micari A, Costa F, Garcia-Ruiz V, De Sio V, Terracciano F, Cesaro A, Moscarella E, Coletta S, Raucci P, Fimiani F, De Luca L, Gargiulo G, Andò G, Calabrò P.

J Clin Med. 2023 Dec 23;13(1):98. doi: 10.3390/jcm13010098.

PMID: 38202105 Free PMC article. Review.

27. [Reply: Unconvinced by Data or Resistance to Change?](#)

Gragnano F, Calabrò P, Mehran R, Valgimigli M; PANTHER Collaboration.

J Am Coll Cardiol. 2024 Jan 2;83(1):e11-e12. doi: 10.1016/j.jacc.2023.10.027.

PMID: 38171714 No abstract available.

28. [Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology.](#)

Andò G, Pelliccia F, Saia F, Tarantini G, Fraccaro C, D'Ascenzo F, Zimarino M, Di Marino M, Niccoli G, Porto I, Calabrò P, Gragnano F, De Rosa S, Piccolo R, Moscarella E, Fabris E, Montone RA, Spaccarotella C, Indolfi C, Sinagra G, Perrone Filardi P; Working Group of

Interventional Cardiology of the Italian Society of Cardiology.

Int J Cardiol. 2024 Apr 1;400:131694. doi: 10.1016/j.ijcard.2023.131694. Epub 2023 Dec 30.

PMID: 38160911 Review.

29. [P2Y₁₂ Inhibitor or Aspirin Monotherapy in Patients with Coronary Artery Disease: is it Time for a Paradigm Shift?](#)

Gragnano F, Capolongo A, Calabrò P.

Curr Vasc Pharmacol. 2024;22(1):1-4. doi: 10.2174/0115701611269735231106110250.

PMID: 38018206 No abstract available.

30. [Choice of P2Y₁₂ Inhibitors After Acute Coronary Syndrome.](#)

Andò G, Gragnano F, Pelliccia F, Calabrò P.

Am J Cardiol. 2024 Jan 15;211:377. doi: 10.1016/j.amjcard.2023.10.084. Epub 2023 Nov 7.

PMID: 37944777 No abstract available.

31. [FLOW trial stopped early due to evidence of renal protection with semaglutide.](#)

Gragnano F, De Sio V, Calabrò P.

Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):7-9. doi: 10.1093/ehjcvp/pvad080.

PMID: 37934595 No abstract available.

32. [Inflammation in patients undergoing transcatheter aortic valve implantation: a therapeutic target for the future?](#)

Gragnano F, DE Sio V, Calabrò P.

Minerva Cardiol Angiol. 2024 Jun;72(3):281-283. doi: 10.23736/S2724-5683.23.06434-7. Epub 2023 Oct 6.

PMID: 37800452 No abstract available.

33. [2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?](#)

Galli M, Andreotti F, Sabouret P, Gragnano F.

Eur Heart J Cardiovasc Pharmacother. 2023 Nov 2;9(7):595-596. doi: 10.1093/ehjcvp/pvad065.

PMID: 37738449 No abstract available.

34. [What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?](#)

Gragnano F, De Sio V, Calabrò P.

Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):673-678. doi: 10.1093/ehjcvp/pvad066.

PMID: 37723607 No abstract available.

35. [Bleeding in Patients Undergoing PCI and TAVR: Combining Coronary and Valve Procedures Raises New Challenges.](#)

Calabrò P, Gragnano F.

JACC Cardiovasc Interv. 2023 Sep 11;16(17):2165-2168. doi: 10.1016/j.jcin.2023.07.036.

PMID: 37704302 No abstract available.

36. [Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go.](#)

Vergara A, De Felice M, Cesaro A, Gragnano F, Pariggiano I, Golia E, De Pasquale A, Blasi E, Fimiani F, Monda E, Limongelli G, Calabrò P.

Angiology. 2024 Nov-Dec;75(10):909-920. doi: 10.1177/00033197231201929. Epub 2023 Sep 12.

PMID: 37699402 Review.

37. [What's new in pharmacotherapy at ESC Congress 2023?](#)

Gragnano F, Calabrò P, Galli M.

Eur Heart J Cardiovasc Pharmacother. 2023 Nov 2;9(7):597-598. doi: 10.1093/ehjcvp/pvad064.

PMID: 37682522 No abstract available.

38. [External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis.](#)

Munafò AR, Montalto C, Franzino M, Pistelli L, Di Bella G, Ferlini M, Leonardi S, D'Ascenzo F, Gragnano F, Oreglia JA, Oliva F, Ortega-Paz L, Calabrò P, Angiolillo DJ, Valgimigli M, Micari A, Costa F.

Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):709-721. doi: 10.1093/ehjcvp/pvad063.

PMID: 37634083

39. [Impact of using risk scores to guide clinical decisions: Do they make a difference?](#)

Gragnano F, De Sio V, Calabrò P.

Int J Cardiol. 2023 Oct 15;389:131264. doi: 10.1016/j.ijcard.2023.131264. Epub 2023 Aug 17.

PMID: 37597811 No abstract available.

40. [Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options.](#)

Cesaro A, De Michele G, Fimiani F, Acerbo V, Scherillo G, Signore G, Rotolo FP, Scialla F, Raucci G, Panico D, Gragnano F, Moscarella E, Scudiero O, Mennitti C, Calabrò P.

Front Cardiovasc Med. 2023 Jul 27;10:1187735. doi: 10.3389/fcvm.2023.1187735. eCollection 2023.

PMID: 37576108 Free PMC article. Review.

41. [Balancing Benefits and Risks of Oral Antiplatelet Strategies in patients With Coronary Artery Diseases: An Evolving Issue.](#)

De Luca L, Gragnano F, Calabrò P, Huber K.

Curr Probl Cardiol. 2023 Dec;48(12):102025. doi: 10.1016/j.cpcardiol.2023.102025. Epub 2023 Aug 6.

PMID: 37553063 Review.

42. [Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease.](#)

Acerbo V, Cesaro A, Scherillo G, Signore G, Rotolo FP, De Michele G, Scialla F, Raucci G, Panico D, Fimiani F, Moscarella E, Gragnano F, Calabrò P.

Heart Fail Rev. 2023 Nov;28(6):1325-1334. doi: 10.1007/s10741-023-10335-0. Epub 2023 Jul 26.

PMID: 37493869 Free PMC article. Review.

43. [SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection.](#)

Gragnano F, Terracciano F, Calabrò P.

J Cardiovasc Transl Res. 2024 Feb;17(1):227-229. doi: 10.1007/s12265-023-10415-4. Epub 2023 Jul 17.

PMID: 37460916 No abstract available.

44. [P2Y₁₂ Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.](#)

Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M; PANTHER Collaboration.

J Am Coll Cardiol. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051.

PMID: 37407118

45. [The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance.](#)

Gragnano F, De Sio V, Calabrò P.

Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):499-501. doi: 10.1093/ehjcvp/pvad043.

PMID: 37358273 No abstract available.

46. [MINOCA Associated with a Myocardial Bridge: Pathogenesis, Diagnosis and Treatment.](#)

Rinaldi R, Princi G, La Vecchia G, Bonanni A, Chiariello GA, Candreva A, Gragnano F, Calabrò P, Crea F, Montone RA.

J Clin Med. 2023 May 31;12(11):3799. doi: 10.3390/jcm12113799.

PMID: 37297993 Free PMC article. Review.

47. [Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry.](#)

Paolisso P, Bergamaschi L, Cesaro A, Gallinoro E, Gragnano F, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Belmonte M, Esposito G, Morici N, Andrea Oreglia J, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Calabrò P, Barbato E,

Marfella R, Pizzi C.

Diabetes Res Clin Pract. 2023 Aug;202:110766. doi: 10.1016/j.diabres.2023.110766. Epub 2023 Jun 3.

PMID: 37276980

48. [De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine.](#)

Gragnano F, Capolongo A, Terracciano F, De Sio V, Maddaluna P, Fimiani F, Moscarella E, Cesaro A, Montone RA, Bianco R, Lisi D, Mensorio MM, Anneschiarico A, Calabrò P.

Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(7):545-551. doi: 10.1080/14779072.2023.2221851. Epub 2023 Jun 5.

PMID: 37267100 Review.

49. [Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives.](#)

Nevola R, Villani A, Imbriani S, Alfano M, Criscuolo L, Beccia D, Ruocco R, Femine AD, Gragnano F, Cozzolino D, Marfella R, Adinolfi LE, Sasso FC, Rinaldi L.

Front Biosci (Landmark Ed). 2023 May 25;28(5):103. doi: 10.31083/j.fbl2805103.

PMID: 37258483 Review.

50. [Reply: DAPT Shortening After Complex PCI: Examining the Fine Print.](#)

Gragnano F, Mehran R, Calabrò P, Valgimigli M; Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration.

J Am Coll Cardiol. 2023 Jun 6;81(22):e193. doi: 10.1016/j.jacc.2023.03.425.

PMID: 37257959 No abstract available.

51. [Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice.](#)

Cesaro A, Acerbo V, Vetrano E, Signore G, Scherillo G, Rotolo FP, De Michele G, Scialla F, Raucci G, Panico D, Gragnano F, Moscarella E, Galiero R, Caturano A, Ruggiero R, Sasso FC, Calabrò P.

Int J Mol Sci. 2023 Apr 30;24(9):8099. doi: 10.3390/ijms24098099.

PMID: 37175805 Free PMC article.

52. [\[Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease\].](#)

Gragnano F, Valgimigli M, Calabrò P.

G Ital Cardiol (Rome). 2023 Apr;24(4 Suppl 2):19S-20S. doi: 10.1714/4035.40101.

PMID: 37158027 Italian. No abstract available.

53. [Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective.](#)

Gragnano F, Pelliccia F, Guarnaccia N, Niccoli G, De Rosa S, Piccolo R, Moscarella E, Fabris E, Montone RA, Cesaro A, Porto I, Indolfi C, Sinagra G, Perrone Filardi P, Andò G, Calabrò P; Working Group of Interventional Cardiology of the Italian Society of Cardiology.

J Clin Med. 2023 Apr 11;12(8):2810. doi: 10.3390/jcm12082810.

PMID: 37109147 Free PMC article. Review.

54. [Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology.](#)

Calabrò P, Spaccarotella C, Cesaro A, Andò G, Piccolo R, De Rosa S, Zimarino M, Mancone M, Gragnano F, Moscarella E, Muscoli S, Romeo F, Barillà F, Filardi PP, Indolfi C, Niccoli G; Interventional Cardiology Working Group of Italian Society of Cardiology.

J Cardiovasc Med (Hagerstown). 2023 Apr 1;24(Suppl 1):e86-e94. doi: 10.2459/JCM.0000000000001440.

PMID: 37052225

55. [The latest news from American College of Cardiology 2023.](#)

Gragnano F, Calabrò P.

Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):297-298. doi: 10.1093/ehjcvp/pvad020.

PMID: 36958850 No abstract available.

56. [Timing and modality of complete revascularization in patients presenting with ST-segment elevation myocardial infarction and multivessel coronary artery disease.](#)

Benatti G, Gragnano F, Vignali L, Calabrò P, Gurgoglione FL, Niccoli G.

Int J Cardiol. 2023 Jun 1;380:6-11. doi: 10.1016/j.ijcard.2023.03.022. Epub 2023 Mar 11.

PMID: 36907453 Review.

57. [P2Y₁₂ Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.](#)

Gragnano F, Mehran R, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM, Kim BK, Watanabe H, Song YB, Zhu Y, Vranckx P, Mehta S, Hong SJ, Ando K, Gwon HC, Calabrò P, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Valgimigli M; Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration.

J Am Coll Cardiol. 2023 Feb 14;81(6):537-552. doi: 10.1016/j.jacc.2022.11.041.

PMID: 36754514

58. [\[New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention\].](#)

Gragnano F, Capolongo A, Terracciano F, Gargiulo G, Cesaro A, Moscarella E, De Sio V, Patti G, Porto I, Esposito G, Calabrò P.

G Ital Cardiol (Rome). 2023 Feb;24(2):99-109. doi: 10.1714/3963.39417.

PMID: 36735308 Review. Italian.

59. [Monitoring antiplatelet therapy: where are we now?](#)
Marcucci R, Berteotti M, Gragnano F, Galli M, Cavallari I, Renda G, Capranzano P, Santilli F, Capodanno D, Angiolillo DJ, Cirillo P, Calabrò P, Patti G, De Caterina R; Working Group of Thrombosis of the Italian Society of Cardiology.
J Cardiovasc Med (Hagerstown). 2023 Apr 1;24(Suppl 1):e24-e35. doi: 10.2459/JCM.0000000000001406. Epub 2022 Dec 15.
PMID: 36729588
60. [Reply to SGLT-2 inhibitors: Post-infarction interventional effects.](#)
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Barbato E, Pizzi C.
Pharmacol Res. 2023 Mar;189:106664. doi: 10.1016/j.phrs.2023.106664. Epub 2023 Jan 13.
PMID: 36642618 Free PMC article. No abstract available.
61. [Physiology-guided revascularization of non-culprit lesions in patients with STEMI: Could vFFR be the way?](#)
Gragnano F, Montalto C, Oreglia JA, Calabrò P.
Int J Cardiol. 2023 May 1;378:20-21. doi: 10.1016/j.ijcard.2023.01.010. Epub 2023 Jan 11.
PMID: 36640962 No abstract available.
62. [Clopidogrel Monotherapy After 1-Month DAPT in Diabetic Patients Undergoing PCI: Is Less Always More?](#)
Cao D, Gragnano F.
JACC Cardiovasc Interv. 2023 Jan 9;16(1):32-35. doi: 10.1016/j.jcin.2022.10.044. Epub 2022 Dec 14.
PMID: 36599585 No abstract available.
63. [\[Gut microbiota and the cardiovascular system: current evidence and future perspectives\].](#)
Gragnano F, Guarnaccia N, Calabrò P.
G Ital Cardiol (Rome). 2023 Jan;24(1):56-57. doi: 10.1714/3934.39180.
PMID: 36573510 Italian. No abstract available.
64. [How has COVID-19 impacted the care of patients with acute coronary syndromes?](#)
Cesaro A, De Michele G, Gragnano F, Calabrò P.
Expert Rev Cardiovasc Ther. 2023 Jan;21(1):1-4. doi: 10.1080/14779072.2023.2159809. Epub 2022 Dec 26.
PMID: 36534926 No abstract available.
65. [Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.](#)

Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E.

Pharmacol Res. 2023 Jan;187:106597. doi: 10.1016/j.phrs.2022.106597. Epub 2022 Dec 5.

PMID: 36470546 Free PMC article.

66. [Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology.](#)

Patti G, Cavallari I, Cesaro A, Gragnano F, Riva L, Fimiani F, Cuccia C, Fresco C, Calabrò P, Leonardi S, Marcucci R, Rubboli A.

Vascul Pharmacol. 2023 Feb;148:107137. doi: 10.1016/j.vph.2022.107137. Epub 2022 Dec 1.

PMID: 36464086 Review.

67. [Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial.](#)

Gragnano F, Pelliccia F, Cesaro A, Calabrò P.

Int J Cardiol. 2023 Jan 15;371:132-134. doi: 10.1016/j.ijcard.2022.09.003. Epub 2022 Sep 9.

PMID: 36089159 No abstract available.

68. [Use of Cangrelor in Older Patients: Findings from the itAlian pRospective Study on CANGrELOr Study.](#)

Capranzano P, Calabrò P, Musumeci G, Mario CD, Chirillo F, Rolfo C, Menozzi A, Menichelli M, Maffeo D, Talanas G, Ferlini M, Contarini M, Lanzilotti V, De Luca L.

Am J Cardiol. 2024 Dec 21;240:31-37. doi: 10.1016/j.amjcard.2024.12.021. Online ahead of print.

PMID: 39716523

69. [Sex-related differences in response to lomitapide in HoFH: A subanalysis of the Pan-European Lomitapide retrospective observational study.](#)

Pavanello C, Suppressa P, Castiglione S, Di Costanzo A, Tramontano D, Rizzi L, Steward K, Calabresi L, Arca M, Roeters van Lennep J, D'Erasmus L; Italian and European Working Group on Lomitapide in HoFH.

Atherosclerosis. 2025 Feb;401:119089. doi: 10.1016/j.atherosclerosis.2024.119089. Epub 2024 Dec 13.

PMID: 39708636

70. [Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial.](#)

Reynolds HR, Page CB, Shaw LJ, Berman DS, Chaitman BR, Picard MH, Kwong RY, Min JK, Leipsic J, Mancini GBJ, Budoff MJ, Hague CJ, Senior R, Szwed H, Bhargava B, Celutkiene J, Gadkari M, Bainey KR, Doerr R, Ramos RB, Ong P, Naik SR, Steg PG,

Goetschalckx K, Chow BJW, Scherrer-Crosbie M, Phillips L, Mark DB, Spertus JA, Alexander KP, O'Brien SM, Boden WE, Bangalore S, Stone GW, Maron DJ, Hochman JS; ISCHEMIA Research Group.

Circ Cardiovasc Interv. 2024 Dec;17(12):e013743. doi: 10.1161/CIRCINTERVENTIONS.123.013743. Epub 2024 Dec 17.

PMID: 39689188 Clinical Trial.

71. [Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study \(CHOLINET Registry\).](#)

Gargiulo P, Marzano F, Crisci M, Marcucci R, Bruzzese D, Maloberti A, Sarullo FM, Galasso G, Indolfi C, Musumeci G, Corleto A, Calabrò P, Carugo S, Casu G, Picciolo A, Ciccone MM, Bilato C, Polimeni A, Giallauria F, Catalano A, De Luca L, Niccoli G, Venturini E, Pepe M, Montisci R, Brunetti ND, Patti G, Porto I, Margonato A, Floresta M, Muscoli S, Cameli M, Andò G, Di Lorenzo E, Berteotti M, Giannattasio C, Sarullo S, Formisano C, Di Costanzo A, Delnevo F, Varbella F, Cesaro A, Franzese M, Mancusi C, Fontanarosa S, Di Santo M, Cotticelli C, Perrone Filardi F, Paolillo S, Esposito G, Corsini A, Perrone Filardi P; CHOLINET Investigators.

J Am Coll Cardiol. 2025 Feb 11;85(5):536-540. doi: 10.1016/j.jacc.2024.10.106. Epub 2024 Dec 11.

PMID: 39665700 No abstract available.

72. [Treatment options for hypertrophic obstructive cardiomyopathy: a patient-centric review.](#)

Cirillo C, Perillo A, Monda E, Palmiero G, Verrillo F, Rubino M, Diana G, Dongiglio F, Caiazza M, Cirillo A, Fusco A, Fumagalli C, Bossone E, Russo MG, Calabro P, Limongelli G.

Expert Rev Cardiovasc Ther. 2024 Nov;22(11):625-637. doi: 10.1080/14779072.2024.2436659. Epub 2024 Dec 5.

PMID: 39633307 Review.

73. [Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk.](#)

Roffi M, Landi A, Heg D, Frigoli E, Chalkou K, Chevalier B, Ijsselmuiden AJJ, Kastberg R, Komiyama N, Morice MC, Onuma Y, Ozaki Y, Peace A, Pyxaras S, Sganzerla P, Williams R, Xaplanteris P, Vranckx P, Windecker S, Smits PC, Valgimigli M; MASTER DAPT Investigators.

JACC Cardiovasc Interv. 2024 Nov 25;17(22):2664-2677. doi: 10.1016/j.jcin.2024.08.030.

PMID: 39603779 Clinical Trial.

74. [Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study.](#)

European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC).

Lancet Diabetes Endocrinol. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3. Epub 2024 Oct 4.

PMID: 39374602

75. [\[Hypercholesterolemia and laboratory reports: joint document from the Italian Society of Cardiology \(SIC\) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine \(SIBioC\)\].](#)
Paolillo S, Graziani MS, Indolfi C, Zaninotto M, Calabrò P, Ceriotti F, Barillà F, Clerico A, Ciccone MM, Trenti T, Porto I, Ciaccio M, Cesaro A, Fontanarosa S, Plebani M, Perrone Filardi P.
G Ital Cardiol (Rome). 2024 Oct;25(10):756-762. doi: 10.1714/4336.43219.
PMID: 39342561 Italian.
76. [Secondary prevention and extreme cardiovascular risk evaluation \(SEVERE-0\): Prevalence of extreme cardiovascular risk in cardiological rehabilitation patients and its impact on functional improvement.](#)
Tognola C, Myriam Intravaia RC, Senini E, Pezzoli S, Riccio A, Gualini E, Fabbri S, Bellantonio V, Politi F, Campana M, Fucile I, Mancusi C, Golia E, Cesaro A, De Luca N, Calabrò P, Giannattasio C, Maloberti A.
Nutr Metab Cardiovasc Dis. 2025 Feb;35(2):103712. doi: 10.1016/j.numecd.2024.08.006. Epub 2024 Aug 10.
PMID: 39289142
77. [Preliminary study on the role of human defensins, interleukins and PCSK9 in early and late preeclampsia.](#)
Mennitti C, Sarno L, Calvanese M, Gentile A, Esposito G, Fulgione C, Orlandi G, Angelino A, Scamardella G, Barretta F, Fimiani F, Cesaro A, Borrelli P, Terracciano D, Pero R, Calabrò P, Frisso G, Guida M, Scudiero O.
Reprod Biol. 2024 Dec;24(4):100947. doi: 10.1016/j.repbio.2024.100947. Epub 2024 Sep 3.
PMID: 39232305
78. [Asundexian versus Apixaban in Patients with Atrial Fibrillation.](#)
Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Ma CS, Goodman SG, Oldgren J, Hammett C, Lopes RD, Akao M, De Caterina R, Kirchhof P, Gorog DA, Hemels M, Rienstra M, Jones WS, Harrington J, Lip GYH, Ellis SJ, Rockhold FW, Neumann C, Alexander JH, Viethen T, Hung J, Coppolecchia R, Mundl H, Caso V; OCEANIC-AF Steering Committee and Investigators.
N Engl J Med. 2025 Jan 2;392(1):23-32. doi: 10.1056/NEJMoa2407105. Epub 2024 Sep 1.
PMID: 39225267 Clinical Trial.
79. [Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up.](#)
Bricoli S, Magnani G, Ardissino M, Maglietta G, Celli P, Ferrario M, Canosi U, Cernetti C, Negri F, Merlini PA, Tubaro M, Berzuini C, Manzalini C, Moschini L, Ponte E, Pozzi R, Buratti S, Botti A, Barocelli F, Biagi A, Bonura R, Bearzot L, Moccetti T, Crocamo A, Notarangelo MF, Moscarella E, Calabrò P, Niccoli G, Ardissino D.
Eur Heart J Acute Cardiovasc Care. 2024 Oct 28;13(10):726-730. doi: 10.1093/ehjacc/zuae089.

PMID: 39107249

80. [Insulin Resistance/Hyperinsulinemia as an Independent Risk Factor That Has Been Overlooked for Too Long.](#)

Fazio S, Affuso F, Cesaro A, Tibullo L, Fazio V, Calabrò P.

Biomedicines. 2024 Jun 26;12(7):1417. doi: 10.3390/biomedicines12071417.

PMID: 39061991 Free PMC article.

81. [Management of Patients Treated With Oral Anticoagulant Therapy Undergoing Percutaneous Coronary Intervention With Stent Implantation: The PERSEO Registry.](#)

Sciahbasi A, De Rosa S, Gargiulo G, Giacoppo D, Calabrò P, Talarico GP, Zilio F, Talanas G, Tebaldi M, Andò G, Rigattieri S, Misuraca L, Cortese B, Musuraca G, Lucci V, Guiducci V, Renda G, Zezza L, Versaci F, Giannico MB, Caruso M, Fischetti D, Colletta M, Santarelli A, Larosa C, Iannone A, Esposito G, Tarantini G, Musumeci G, Rubboli A.

J Cardiovasc Pharmacol. 2024 Oct 1;84(4):457-467. doi: 10.1097/FJC.0000000000001607.

PMID: 39028879

82. [Patterns of Left Ventricular Remodelling in Children and Young Patients with Hypertrophic Cardiomyopathy.](#)

Monda E, Caiazza M, Cirillo C, Rubino M, Verrillo F, Palmiero G, Diana G, Cirillo A, Fusco A, Guarnaccia N, Buono P, Frisso G, Calabrò P, Russo MG, Limongelli G.

J Clin Med. 2024 Jul 4;13(13):3937. doi: 10.3390/jcm13133937.

PMID: 38999502 Free PMC article.

83. [Impact of Tafamidis on Delaying Clinical, Functional, and Structural Cardiac Changes in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy.](#)

Palmiero G, Monda E, Verrillo F, Dongiglio F, Cirillo C, Caiazza M, Rubino M, Cirillo A, Fusco A, Diana G, Ciccarelli G, Dellegrottaglie S, Calabrò P, Golino P, Limongelli G.

J Clin Med. 2024 Jun 26;13(13):3730. doi: 10.3390/jcm13133730.

PMID: 38999296 Free PMC article.

84. [\[SIC Position paper: Treat to prevent the first event - intensive LDL cholesterol lowering in patients at very high cardiovascular risk without a previous cardiovascular event. From ESC guidelines to clinical practice\].](#)

Perrone Filardi P, Nardi E, Agostoni P, Barillà F, Calabrò P, Ciccone MM, Curcio A, Indolfi C, Muscoli S, Nodari S, Paolillo S, Patti G, Porto I, Sinagra G, Gallo L, Fontanarosa S, Vizza CD, Gargiulo P.

G Ital Cardiol (Rome). 2024 Jul;25(7):530-540. doi: 10.1714/4282.42641.

PMID: 38916469 Italian.

85. [Low platelet count at admission has an adverse impact on outcome in patients with acute coronary syndromes: from the START Antiplatelet registry.](#)

Gresele P, Guglielmini G, Del Pinto M, Calabrò P, Pignatelli P, Patti G, Pengo V, Antonucci E, Cirillo P, Fierro T, Palareti G, Marcucci R; START Antiplatelet Registry Group.

Sci Rep. 2024 Jun 24;14(1):14516. doi: 10.1038/s41598-024-64113-5.

PMID: 38914608 Free PMC article.

86. [Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study.](#)

Ray KK, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Laufs U, Mostaza JM, Nanchen D, Bardet A, Lamparter M, Chhabra R, Soronen J, Rietzschel E, Strandberg T, Toplak H, Visseren FLJ, Catapano AL; SANTORINI Study Investigators.

Eur J Prev Cardiol. 2024 Nov 11;31(15):1792-1803. doi: 10.1093/eurjpc/zwae199.

PMID: 38861400

87. [Strike early-stroke strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry.](#)

Gargiulo P, Basile C, Galasso G, Bellino M, D'Elia D, Patti G, Bosco M, Prinetti M, Andò G, Campanella F, Taverna G, Calabrò P, Cesaro A, Fimiani F, Catalano A, Varbella F, Corleto A, Barillà F, Muscoli S, Musumeci G, Delnevo F, Giallauria F, Napoli R, Porto I, Polimeni A, Quarta R, Maloberti A, Merlini PA, De Luca L, Casu G, Brunetti ND, Crisci M, Paloscia L, Bilato C, Indolfi C, Marzano F, Fontanarosa S, Buonocore D, Parlati ALM, Nardi E, Prastaro M, Soricelli A, Salvatore M, Paolillo S, Perrone-Filardi P, Cuomo G, Testa C, Passaretti G, Vallefucio G, Romano A, Dell'Anno R, Merolla A, Iannone FP.

Eur J Prev Cardiol. 2024 Nov 11;31(15):1806-1816. doi: 10.1093/eurjpc/zwae170.

PMID: 38788773

88. [Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.](#)

Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators.

Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025.

PMID: 38658193 Free PMC article. Review.

89. [\[Optimizing the care management pathway of patients with ischemia and non-obstructive coronary arteries\].](#)

Oliva F, Boriani G, Calabrò P, Caldarola P, Carugo S, Castiglioni B, Celentani D, Comeglio M, De Luca L, De Maria R, Di Muro M, Ignone G, Leonardo F, Margonato A, Massari F, Murrone A, Nardi F, Patti G, Perna G, Pinna P, Poli M, Prati F, Raddino R, Pierdomenico SD, Tammaro P, Porto I.

G Ital Cardiol (Rome). 2024 May;25(5):309-317. doi: 10.1714/4252.42294.

PMID: 38639121 Italian.

90. [Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.](#)

Pracoń R, Spertus JA, Broderick S, Bangalore S, Rockhold FW, Ruzyllo W, Demchenko E, Nageh T, Grossman GB, Mavromatis K, Manjunath CN, Smanio PEP, Stone GW, Mancini

GBJ, Boden WE, Newman JD, Reynolds HR, Hochman JS, Maron DJ; ISCHEMIA Research Group.

Circ Cardiovasc Interv. 2024 Jun;17(6):e013435. doi: 10.1161/CIRCINTERVENTIONS.123.013435. Epub 2024 Apr 17.

PMID: 38629312 Clinical Trial.

91. [Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.](#)

Silverio A, Bellino M, Scudiero F, Attisano T, Baldi C, Catalano A, Centore M, Cesaro A, Di Maio M, Esposito L, Granata G, Maiellaro F, Muraca I, Musumeci G, Parodi G, Personeni D, Valenti R, Vecchione C, Calabrò P, Galasso G.

J Thromb Thrombolysis. 2024 Jun;57(5):757-766. doi: 10.1007/s11239-024-02970-7. Epub 2024 Apr 13.

PMID: 38615155

92. [Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry.](#)

Caforio ALP, Kaski JP, Gimeno JR, Elliott PM, Laroche C, Tavazzi L, Tendera M, Fu M, Sala S, Seferovic PM, Heliö T, Calò L, Blagova O, Amin A, Kindermann I, Sinagra G, Frustaci A, Bonnet D, Charron P, Maggioni AP; CMY Registry Investigators.

Eur Heart J. 2024 Jul 21;45(28):2548-2569. doi: 10.1093/eurheartj/ehae169.

PMID: 38594778

93. [Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.](#)

Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA; AEGIS-II Committees and Investigators.

N Engl J Med. 2024 May 2;390(17):1560-1571. doi: 10.1056/NEJMoa2400969. Epub 2024 Apr 6.

PMID: 38587254 Clinical Trial.

94. [Alternative Approaches for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: The Call for a Personalized Treatment.](#)

Pelliccia F, Moscarella E, Calabrò P, Andò G.

Am J Cardiol. 2024 Apr 15;217:164-166. doi: 10.1016/j.amjcard.2024.03.011. Epub 2024 Mar 13.

PMID: 38490337 No abstract available.

95. [Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial.](#)

Reynolds HR, Cyr DD, Merz CNB, Shaw LJ, Chaitman BR, Boden WE, Alexander KP, Rosenberg YD, Bangalore S, Stone GW, Held C, Spertus J, Goetschalckx K, Bockeria O, Newman JD, Berger JS, Elghamazy A, Lopes RD, Min JK, Berman DS, Picard MH, Kwong RY, Harrington RA, Thomas B, O'Brien SM, Maron DJ, Hochman JS; ISCHEMIA Research Group *.

J Am Heart Assoc. 2024 Mar 5;13(5):e029850. doi: 10.1161/JAHA.122.029850. Epub 2024 Feb 27.

PMID: 38410945 Free PMC article. Clinical Trial.

96. [Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.](#)

D'Erasmus L, Bini S, Casula M, Gazzotti M, Bertolini S, Calandra S, Tarugi P, Averna M, Iannuzzo G, Fortunato G, Catapano AL, Arca M; LIPIGEN HoFH group.

Eur J Prev Cardiol. 2024 Jun 3;31(8):1038-1047. doi: 10.1093/eurjpc/zwae036.

PMID: 38374534

97. [Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia.](#)

Mulder JWCM, Tromp TR, Al-Khnefawi M, Blom DJ, Chlebus K, Cuchel M, D'Erasmus L, Gallo A, Hovingh GK, Kim NT, Long J, Raal FJ, Schonck WAM, Soran H, Truong TH, Boersma E, Roeters van Lennep JE; Homozygous Familial Hypercholesterolemia International Clinical Collaborators.

JAMA Cardiol. 2024 Apr 1;9(4):313-322. doi: 10.1001/jamacardio.2023.5597.

PMID: 38353972 Free PMC article.

98. [GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.](#)

Marfella R, Prattichizzo F, Sardù C, Rambaldi PF, Fumagalli C, Marfella LV, La Grotta R, Frigé C, Pellegrini V, D'Andrea D, Cesaro A, Calabrò P, Pizzi C, Antonicelli R, Ceriallo A, Mauro C, Paolisso G.

Cardiovasc Diabetol. 2024 Jan 6;23(1):10. doi: 10.1186/s12933-023-02118-6.

PMID: 38184582 Free PMC article.

99. [Safety and efficacy of everolimus-eluting bioresorbable vascular scaffold for cardiac allograft vasculopathy \(CART\).](#)

Pighi M, Tomai F, Fezzi S, Pesarini G, Petrolini A, Spedicato L, Tarantini G, Ferlini M, Calabrò P, Loi B, Ferrero V, Forero MNT, Daemen J, Ribichini F.

Clin Res Cardiol. 2024 Jul;113(7):1017-1029. doi: 10.1007/s00392-023-02351-9. Epub 2024 Jan 3.

PMID: 38170246

100. [Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study.](#)

European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration.

Lancet. 2024 Jan 6;403(10421):55-66. doi: 10.1016/S0140-6736(23)01842-1. Epub 2023 Dec 12.

PMID: 38101429

101. [Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.](#)

Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators.

Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5.

PMID: 38048573 Clinical Trial.

102. [Secondary Prevention and Extreme Cardiovascular Risk Evaluation \(SEVERE-1\), Focus on Prevalence and Associated Risk Factors: The Study Protocol.](#)

Maloberti A, Intravaia RCM, Mancusi C, Cesaro A, Golia E, Ilaria F, Coletta S, Merlini P, De Chiara B, Bernasconi D, Algeri M, Ossola P, Ciampi C, Riccio A, Tognola C, Ardissino M, Inglese E, Scaglione F, Calabrò P, De Luca N, Giannattasio C.

High Blood Press Cardiovasc Prev. 2023 Nov;30(6):573-583. doi: 10.1007/s40292-023-00607-z. Epub 2023 Nov 30.

PMID: 38030852 Free PMC article.

103. [Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.](#)

Landi A, Alasnag M, Heg D, Frigoli E, Malik FTN, Gomez-Blazquez I, Pourbaix S, Chieffo A, Spaulding C, Sainz F, Routledge H, Andò G, Testa L, Sciahbasi A, Contractor H, Jepson N, Mieres J, Imran SS, Noor H, Smits PC, Valgimigli M; MASTER DAPT Investigators.

JAMA Cardiol. 2024 Jan 1;9(1):35-44. doi: 10.1001/jamacardio.2023.4316.

PMID: 37991745 Free PMC article. Clinical Trial.

104. [Prediction of incident atrial fibrillation in hypertrophic cardiomyopathy.](#)

Losi MA, Monda E, Lombardi R, Lioncino M, Canciello G, Rubino M, Todde G, Caiazza M, Borrelli F, Fusco A, Cirillo A, Perillo EF, Sepe J, Pacella D, de Simone G, Calabro P, Esposito G, Limongelli G.

Int J Cardiol. 2024 Jan 15;395:131575. doi: 10.1016/j.ijcard.2023.131575. Epub 2023 Nov 10.

PMID: 37951419

105. [Coronary calcification in patients presenting with acute coronary syndromes: insights from the MATRIX trial.](#)

Sanz-Sanchez J, Garcia-Garcia HM, Branca M, Frigoli E, Leonardi S, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Vranckx P, Valgimigli M.

Eur Heart J Acute Cardiovasc Care. 2023 Nov 16;12(11):782-791. doi: 10.1093/ehjacc/zuad122.

PMID: 37812760

106. [Prevalence and predictive role of hypertriglyceridemia in statin-treated patients at very high risk: Insights from the START study.](#)

De Luca L, Temporelli PL, Gulizia MM, Gonzini L, Ammaturo TA, Tedesco L, Pede S, Oliva F, Gabrielli D, Colivicchi F, Averna MR; START Investigators.

Nutr Metab Cardiovasc Dis. 2023 Dec;33(12):2398-2405. doi: 10.1016/j.numecd.2023.07.036. Epub 2023 Aug 7.

PMID: 37788956

107. [\[How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy\].](#)

Arca M, Averna M, Borghi C, Lettino M, Perrone Filardi P, Alberti A, Bilato C, Calabrò P, Carubbi F, Ciccone MM, Cipollone F, Citroni N, De Luca L, Giaccari A, Iannuzzo G, Maloberti A, Marcucci R, Pignatelli Spinazzola P, Pirro M, Pisciotto L, Sarullo F, Sciacqua A, Suppressa P, Varbella F, Werba JP, Zambon A.

G Ital Cardiol (Rome). 2023 Oct;24(10):770-780. doi: 10.1714/4100.40977.

PMID: 37767829 Review. Italian.

108. [Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.](#)

Casula M, Gazzotti M, Capra ME, Olmastroni E, Galimberti F, Catapano AL, Pederiva C; LIPIGEN Group and the LIPIGEN Paediatric Group.

Atherosclerosis. 2023 Nov;385:117231. doi: 10.1016/j.atherosclerosis.2023.117231. Epub 2023 Aug 12.

PMID: 37648636

109. [Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.](#)

Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, Cerrato E, Sacchetta G, Jurado-Roman A, Menozzi A, Amat Santos I, Díez Gil JL, Ruozzi M, Barbierato M, Fileti L, Picchi A, Lodolini V, Biondi-Zoccai G, Maietti E, Pavasini R, Cimaglia P, Tumscitz C, Erriquez A, Penzo C, Colaiori I, Pignatelli G, Casella G, Iannopolo G, Menozzi M, Varbella F, Caretta G, Dudek D, Barbato E, Tebaldi M, Campo G; FIRE Trial Investigators.

N Engl J Med. 2023 Sep 7;389(10):889-898. doi: 10.1056/NEJMoa2300468. Epub 2023 Aug 26.

PMID: 37634150 Clinical Trial.

110. [Closing the gap between WHO projections and actual need for cardiac rehabilitation in Europe.](#)

Morici N, Ambrosetti M, Cianflone D, Calabrò P, Piepoli M.

Eur J Prev Cardiol. 2024 Nov 18;31(16):e115-e116. doi: 10.1093/eurjpc/zwad277.

PMID: 37610737 No abstract available.

111. [Validation of a Contemporary Acute Kidney Injury Risk Score in Patients With Acute Coronary Syndrome.](#)

Landi A, Chiarito M, Branca M, Frigoli E, Gagnor A, Calabrò P, Briguori C, Andò G, Repetto A, Limbruno U, Sganzerla P, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, Varbella F, Heg D, Mehran R, Valgimigli M.

JACC Cardiovasc Interv. 2023 Aug 14;16(15):1873-1886. doi: 10.1016/j.jcin.2023.06.015.

PMID: 37587595 Clinical Trial.

112. [Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.](#)

Piccolo R, Calabrò P, Varricchio A, Baldi C, Napolitano G, De Simone C, Mauro C, Stabile E, Caiazza G, Tesorio T, Boccalatte M, Tuccillo B, Bottiglieri G, Russolillo E, Di Lorenzo E, Carrara G, Cassese S, Leonardi S, Biscaglia S, Costa F, McFadden E, Heg D, Franzone A, Stefanini GG, Capodanno D, Esposito G.

Am Heart J. 2023 Nov;265:153-160. doi: 10.1016/j.ahj.2023.08.001. Epub 2023 Aug 10.

PMID: 37572785 Clinical Trial.

113. [Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group.](#)

Pederiva C, Gazzotti M, Arca M, Averna M, Banderali G, Biasucci G, Brambilla M, Buonuomo PS, Calabrò P, Cipollone F, Citroni N, D'Addato S, Del Ben M, Genovesi S, Guardamagna O, Iannuzzo G, Iughetti L, Mandraffino G, Maroni L, Mombelli G, Muntoni S, Nascimbeni F, Passaro A, Pellegatta F, Pirro M, Pisciotta L, Pujia R, Sarzani R, Scicali R, Suppressa P, Zambon S, Zenti MG, Calandra S, Catapano AL, Tarugi P, Galimberti F, Casula M, Capra ME.

Nutrients. 2023 Aug 5;15(15):3468. doi: 10.3390/nu15153468.

PMID: 37571405 Free PMC article.

114. [Reproducibility of an artificial intelligence optical coherence tomography software for tissue characterization: Implications for the design of longitudinal studies.](#)

Garg M, Garcia-Garcia HM, Calderón AT, Gupta J, Sortur S, Levine MB, Singla P, Picchi A, Sardella G, Adamo M, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Sánchez JS, Valgimigli M.

Cardiovasc Revasc Med. 2024 Jan;58:79-87. doi: 10.1016/j.carrev.2023.07.003. Epub 2023 Jul 16.

PMID: 37474355

115. [Prevalence and clinical significance of right ventricular pulmonary arterial uncoupling in cardiac amyloidosis.](#)

Palmiero G, Monda E, Verrillo F, Dongiglio F, Caiazza M, Rubino M, Lioncino M, Diana G, Vetrano E, Fusco A, Cirillo A, Mauriello A, Ciccarelli G, Ascione L, De Rimini ML, D'Alto M,

Cerciello G, D'Andrea A, Golino P, Calabrò P, Bossone E, Limongelli G.

Int J Cardiol. 2023 Oct 1;388:131147. doi: 10.1016/j.ijcard.2023.131147. Epub 2023 Jul 7.

PMID: 37423570

116. [Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque.](#)

Marfella R, Prattichizzo F, Sardu C, Paolisso P, D'Onofrio N, Scisciola L, La Grotta R, Frigé C, Ferraraccio F, Panarese I, Fanelli M, Modugno P, Calafiore AM, Melchionna M, Sasso FC, Furbatto F, D'Andrea D, Siniscalchi M, Mauro C, Cesaro A, Calabrò P, Santulli G, Balestrieri ML, Barbato E, Cerciello A, Paolisso G.

Atherosclerosis. 2023 Aug;378:117180. doi: 10.1016/j.atherosclerosis.2023.06.971. Epub 2023 Jun 29.

PMID: 37422356

117. [Artificial intelligence in cardiovascular prevention: new ways will open new doors.](#)

Ciccarelli M, Giallauria F, Carrizzo A, Visco V, Silverio A, Cesaro A, Calabrò P, De Luca N, Mancusi C, Masarone D, Pacileo G, Tourkmani N, Vigorito C, Vecchione C.

J Cardiovasc Med (Hagerstown). 2023 May 1;24(Suppl 2):e106-e115. doi: 10.2459/JCM.0000000000001431.

PMID: 37186561 Review.

118. [Lipoprotein\(a\) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia.](#)

Olmastroni E, Gazzotti M, Aversa M, Arca M, Tarugi P, Calandra S, Bertolini S, Catapano AL, Casula M; LIPIGEN Study Group *.

J Am Heart Assoc. 2023 May 16;12(10):e029223. doi: 10.1161/JAHA.122.029223. Epub 2023 May 15.

PMID: 37183858 Free PMC article.

119. [\[Uncertainties in cardiovascular risk factors: sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity?\].](#)

Avogaro A, Corsini A, Sinagra G, Borghi C, Sciatti E, Trevisan R, Fioretto P, Calabrò P, Di Pasquale G, Senni M.

G Ital Cardiol (Rome). 2023 May;24(5):337-343. doi: 10.1714/4026.40007.

PMID: 37102346 Italian.

120. [Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study.](#)

Palmiero G, Cesaro A, Galiero R, Loffredo G, Caturano A, Vetrano E, Rinaldi L, Salvatore T, Ruggiero R, Rosaria Di Palo M, Sardu C, Marfella R, Limongelli G, Calabrò P, Carlo Sasso F.

Diabetes Res Clin Pract. 2023 Jun;200:110686. doi: 10.1016/j.diabres.2023.110686. Epub 2023 Apr 25.

PMID: 37100231

121. [SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis.](#)

Sardu C, Trotta MC, Sasso FC, Sacra C, Carpinella G, Mauro C, Minicucci F, Calabrò P, D' Amico M, D' Ascenzo F, De Filippo O, Iannaccone M, Pizzi C, Paolisso G, Marfella R.

Cardiovasc Diabetol. 2023 Apr 1;22(1):80. doi: 10.1186/s12933-023-01814-7.

PMID: 37005586 Free PMC article.

122. [Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.](#)

Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators.

Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7.

PMID: 36927680 Free PMC article. Clinical Trial.

123. [Time for implementing high-sensitivity cardiac troponin assays in emergency departments in Italy.](#)

Moscarella E, Calabrò P.

Intern Emerg Med. 2023 Apr;18(3):689-690. doi: 10.1007/s11739-023-03225-8. Epub 2023 Mar 1.

PMID: 36859648 No abstract available.

124. [Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy.](#)

Monda E, Rubino M, Palmiero G, Verrillo F, Lioncino M, Diana G, Cirillo A, Fusco A, Dongiglio F, Caiazza M, Altobelli I, Mauriello A, Guarnaccia N, Scatteia A, Cesaro A, Pacileo G, Sarubbi B, Frisso G, Bauce B, D'Andrea A, Dellegrottaglie S, Russo MG, Calabrò P, Limongelli G.

J Clin Med. 2023 Feb 16;12(4):1568. doi: 10.3390/jcm12041568.

PMID: 36836107 Free PMC article. Review.

125. [Transient vs In-Hospital Persistent Acute Kidney Injury in Patients With Acute Coronary Syndrome.](#)

Landi A, Branca M, Leonardi S, Frigoli E, Vranckx P, Tebaldi M, Varbella F, Calabrò P, Esposito G, Sardella G, Garducci S, Andò G, Limbruno U, Sganzerla P, Santarelli A, Briguori C, Colangelo S, Brugaletta S, Adamo M, Omerovic E, Heg D, Windecker S, Valgimigli M; MATRIX Investigators.

JACC Cardiovasc Interv. 2023 Jan 23;16(2):193-205. doi: 10.1016/j.jcin.2022.10.009. Epub 2022 Dec 28.

PMID: 36697156 Clinical Trial.

126. [Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study \(AT-TARGET-IT\).](#)
Gargiulo P, Basile C, Cesaro A, Marzano F, Buonocore D, Asile G, Abbate V, Vicidomini F, Paolillo S, Spaccarotella CAM, Catalano A, Spirito G, Merlini PA, Maloberti A, Iannuzzo G, Ciccone MM, Zito AP, Paloscia L, D'Alleva A, Varbella F, Corleto A, Brunetti ND, Corbo MD, Calabrò P, Indolfi C, Perrone-Filardi P.
Atherosclerosis. 2023 Feb;366:32-39. doi: 10.1016/j.atherosclerosis.2023.01.001. Epub 2023 Jan 13.
PMID: 36696749
127. [The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases.](#)
Monda E, Lioncino M, Verrillo F, Rubino M, Caiazza M, Mauriello A, Guarnaccia N, Fusco A, Cirillo A, Covino S, Altobelli I, Diana G, Palmiero G, Dongiglio F, Natale F, Cesaro A, Bossone E, Russo MG, Calabrò P, Limongelli G.
Diagnostics (Basel). 2023 Feb 17;13(4):772. doi: 10.3390/diagnostics13040772.
PMID: 36832261 Free PMC article. Review.
128. [SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes.](#)
Marfella R, Sardu C, D'Onofrio N, Fumagalli C, Scisciola L, Sasso FC, Siniscalchi M, Marfella LV, D'Andrea D, Minicucci F, Signoriello G, Cesaro A, Trotta MC, Frigé C, Prattichizzo F, Balestrieri ML, Ceriello A, Calabrò P, Mauro C, Del Viscovo L, Paolisso G.
BMC Med. 2023 Feb 24;21(1):71. doi: 10.1186/s12916-023-02781-2.
PMID: 36829203 Free PMC article.
129. [Aortic Root Diameter in Highly-Trained Competitive Athletes: Reference Values According to Sport and Prevalence of Aortic Enlargement.](#)
Limongelli G, Monda E, Lioncino M, Di Paolo F, Ferrara F, Vrizz O, Calabro P, Bossone E, Pelliccia A.
Can J Cardiol. 2023 Jul;39(7):889-897. doi: 10.1016/j.cjca.2023.02.010. Epub 2023 Feb 19.
PMID: 36803973
130. [Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis.](#)
Dongiglio F, Monda E, Palmiero G, Verrillo F, Rubino M, Diana G, Cirillo A, Fusco A, Vetrano E, Lioncino M, Caiazza M, Cerciello G, Capodicasa L, Chiosi F, Simonelli V, De Rimini ML, Natale F, Di Santo A, Moscarella E, Calabrò P, Limongelli G.
J Clin Med. 2023 Jan 9;12(2):528. doi: 10.3390/jcm12020528.
PMID: 36675458 Free PMC article. Review.
131. [Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.](#)
Larrey D, D'Erasmo L, O'Brien S, Arca M; Italian Working Group on Lomitapide.
Liver Int. 2023 Feb;43(2):413-423. doi: 10.1111/liv.15497. Epub 2022 Dec 30.

PMID: 36520008 Free PMC article. Clinical Trial.

132. [Survival After Invasive or Conservative Management of Stable Coronary Disease.](#)

Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, Mavromichalis S, Chang M, Contreras A, Rosenberg Y, Kirby R, Bhargava B, Senior R, Banfield A, Goodman SG, Lopes RD, Pracoń R, López-Sendón J, Maggioni AP, Newman JD, Berger JS, Sidhu MS, White HD, Troxel AB, Harrington RA, Boden WE, Stone GW, Mark DB, Spertus JA, Maron DJ; ISCHEMIA-EXTEND Research Group.

Circulation. 2023 Jan 3;147(1):8-19. doi: 10.1161/CIRCULATIONAHA.122.062714. Epub 2022 Nov 6.

PMID: 36335918 Free PMC article. Clinical Trial.

132. [Five-year clinical outcomes of STEMI patients treated with a pre-specified bioresorbable vascular scaffold implantation technique: Final results of the BVS STEMI STRATEGY-IT.](#)

Moscarella E, Campo G, Leoncini M, Geraci S, Nicolini E, Cortese B, Loi B, Guiducci V, Saccà S, Varricchio A, Vicinelli P, De Candia G, Personeni D, Calabrò P, Brugaletta S, Latib A, Tespili M, Ielasi A.

Cardiovasc Revasc Med. 2024 Nov 7:S1553-8389(24)00715-2.

doi: 10.1016/j.carrev.2024.11.003. Online ahead of print. PMID: 39547832

133 [QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial.](#)

Erriquez A, Campo G, Guiducci V, Casella G, Menozzi M, Cerrato E, Sacchetta G, Moreno R, Arena M, Amat Santos I, Diez Gil JL, Scarsini R, Ruozzi M, Ariotti M, Picchi A, Barbierato M, Moscarella E, Musto D'Amore S, Lanzilotti V, Cavazza C, Rezzaghi M, Cocco M, Marrone A, Verardi FM, Escaned J, Barbato E, Colaiori I, Pesenti N, Carrara G, Biscaglia S.

JACC Cardiovasc Interv. 2024 Jun 24;17(12):1425-1436.

doi: 10.1016/j.jcin.2024.04.022. Epub 2024 May 14.

134 [Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis.](#)

Moscarella E, Ielasi A, Montonati C, Pellegrini D, Pellicano M, Briguglia D, D'Alessandro V, Giannini F, Gamardella M, Medda M, Guagliumi G, Banfi C, Glauber M, Tespili M.

Int J Cardiol. 2024 Apr 1;400:131701.

doi: 10.1016/j.ijcard.2023.131701. Epub 2023 Dec 31. PMID: 38168557

135 [Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience.](#)

Moscarella E, Ielasi A, Mussayev A, Montorfano M, Mullassari A, Martin P, Testa L, Jose J, Ninios V, Toutouzas K, Giannini F, Kertesz A, Unic D, Nissen H, Ezhumalai B, Senguttuvan NB, Amat-Santos I, Seth A, Bedogni F, Tespili M.

Int J Cardiol. 2023 Apr 1;376:35-45.

doi: 10.1016/j.ijcard.2023.01.017. Epub 2023 Jan 16.PMID: 36657566

- 136 [Hypercholesterolemia and laboratory reports: joint document from the Italian Society of Cardiology \(SIC\) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine \(SIBioC\).](#)

Paolillo S, Graziani MS, Indolfi C, Zaninotto M, Calabrò P, Ceriotti F, Barillà F, Clerico A, Ciccone MM, Trenti T, Porto I, Ciaccio M, Cesaro A, Fontanarosa S, Plebani M, Perrone Filardi P.G Ital Cardiol (Rome).

2024 Oct;25(10):756-762. doi: 10.1714/4336.43219.

- 137 [The clinical relevance of the reversal of coronary atherosclerotic plaque.](#)

Cesaro A, Acerbo V, Indolfi C, Filardi PP, Calabrò P.Eur J Intern Med.

2024 Nov;129:16-24. doi: 10.1016/j.ejim.2024.08.010. Epub 2024 Aug 19.

- 138 [Lipoproteina\(a\): associazione con la malattia aterosclerotica e valvolare e terapie emergenti \[Lipoprotein\(a\): relationships with atherosclerosis and valvular heart disease, and emerging therapies\].](#)

Abrignani MG, Maloberti A, Di Fusco SA, Lucà F, Cesaro A, Acerbo V, Fabbri S, Di Matteo I, Amico AF, Temporelli PL, Riccio C, Colivicchi F, Grimaldi M, Gabrielli D, Oliva F.

G Ital Cardiol (Rome). 2024 Feb;25(2):76-87. Italian. doi: 10.1714/4187.41756.

- 139 [Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem.](#)

Abrignani MG, Gronda E, Marini M, Gori M, Iacoviello M, Temporelli PL, Benvenuto M, Binaghi G, Cesaro A, Maloberti A, Tinti MD, Riccio C, Colivicchi F, Grimaldi M, Gabrielli D, Oliva F; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Working Groups on Cardiological Chronicity, Cardioresnal, Metabolic, Heart Failure.

Cardiovasc Drugs Ther. 2024 Jan 30. doi: 10.1007/s10557-024-07551-7.

- 140 [Malattia aterosclerotica polidistrettuale: inquadramento epidemiologico e clinico \[Multidistrict atherosclerotic disease: epidemiological and clinical framework\].](#)

Di Fusco SA, Abrignani MG, Amico AF, Lucà F, Mureddu GF, Ceravolo R, Temporelli PL, Acerbo V, Altamura V, Baccino D, Binaghi G, Bugani G, **Cesaro A**, Ciccirillo F, Cocozza S, D'Errigo P, Di Martino M, Di Nora C, Fileti L, Lopriore V, Maloberti A, Monitillo F, Gulizia MM, Grimaldi M, Gabrielli D, Oliva F, Colivicchi F.

G Ital Cardiol (Rome). 2024 Apr;25(4):239-251. Italian. doi: 10.1714/4244.42205.